ReviewBiomedicines2025

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.

Aryan Gajjar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.